Effect of Doxazosin on Insulin Resistance in Hypertensive Patients with Obesity

Hormone and Metabolic Research

Volumn 35, Issue 9, 2003, Pages 532-536

  Ueshiba, H ^a   Miyachi, Y ^a  

^a TOHO UNIVERSITY   (Japan)

Author keywords

Adrenergic Alpha Antagonists; Doxazosin; Hypertension; Insulin; Leptin; Obesity; Tumor Necrosis Factor

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; DOXAZOSIN; INSULIN; LEPTIN; TUMOR NECROSIS FACTOR;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; FEMALE; HUMAN; HYPERTENSION; IMMUNOREACTIVITY; INSULIN RESISTANCE; MALE; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE;

ADIPOSE TISSUE; ADRENERGIC ALPHA-ANTAGONISTS; ADULT; ANALYSIS OF VARIANCE; DOXAZOSIN; FEMALE; HUMANS; HYPERINSULINISM; HYPERLIPIDEMIAS; HYPERTENSION; INSULIN RESISTANCE; LINEAR MODELS; MALE; MIDDLE AGED; OBESITY;

EID: 0141921956     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-42654     Document Type: Article

References (31)

1. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. The continuing epidemics of obesity and diabetes in the United States. JAMA 2001; 286: 1195-1200
2. McLaughlin T, Abbasi F, Kim HS, Lamendola C, Schaaf P, Reaven G. Relationship between insulin resistance, weight loss, and coronary heart disease risk in healthy, obese women. Metabolism 2001; 50: 795-800
3. McLaughlin T, Reaven G. Insulin resistance and hypertension. Patients in double jeopardy for cardiovascular disease. Geriatrics 2000; 55: 28-32, 35
4. Valantine H, Rickenbacker P, Kemna M, Hunt S, Chen YD, Reaven G et al. Metabolic abnormalities characteristic of dysmetabolic syndrome predict the development of transplant coronary artery disease: a prospective study. Circulation 2001; 103: 2144-2152
5. Ahima RS, Flier JS. Adipose tissue as an endocrine organ. Trends Endocrinol Metab 2000; 11: 327-332
6. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91
7. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995; 95: 2409-2415
8. Kirchgessner TG, Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Tumor necrosis factor-alpha contributes to obesity-related hyperleptinemia by regulating leptin release from adipocytes. J Clin Invest 1997; 100: 2777-2782
9. Coleman DL. Obese and diabetes: two mutant genes causing diabetes-obesity syndromes in mice. Diabetologia 1978; 14: 141-148
10. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996; 334: 292-295
11. Kageyama S, Yamamoto J, Mimura A, Sakurai T, Ishibashi K, Aihara K et al. Doxazosin improves insulin sensitivity in hypertensive patients. Clin Ther 1993; 15: 829-837
12. Giorda C, Appendino M. Effects of doxazosin, a selective alpha 1-inhibitor, on plasma insulin and blood glucose response to a glucose tolerance test in essential hypertension. Metabolism 1993; 42: 1440-1442
13. Andersson PE, Johansson J, Berne C, Lithell H. Effects of selective alfa 1 and beta 1-adrenoreceptor blockade on lipoprotein and carbohydrate metabolism in hypertensive subjects, with special emphasis on insulin sensitivity. J Hum Hypertens 1994; 8: 219-226
14. Andersson PE, Lithell H. Metabolic effects of doxazosin and enalapril in hypertriglyceridemic, hypertensive men. Relationship to changes in skeletal muscle blood flow. Am J Hypertens 1996; 9: 323-333
15. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419
16. Calo L, Davis PA, Cantaro S, Bonfante L, Castrignano R, Carraro G et al. Effect of doxazosin in mild to moderate hypertensive patients with insulin-dependent diabetes mellitus. Acta Diabetol 1998; 35: 96-100
17. Toth K, Nemes J, Czopf L, Kapronczay P, Kesmarky G. Juricskay I. Effects of doxazosin on hemorheological, hemodynamic and lipid parameters in patients with essential hypertension. Clin Hemorheol Microcirc 1999; 20: 57-61
18. Shionoiri H, Ashino K, Yamanaka K, Shindo K, Hiroto S, Arita T. Effect of doxazosin therapy on glucose tolerance and lipid metabolism in hypertensive patients with impaired glucose tolerance. Clin Ther 1997; 19: 527-536
19. Hirano T, Yoshino G, Kashiwazaki K, Adachi M. Doxazosin reduces prevalence of small dense low density lipoprotein and remnant-like particle cholesterol levels in nondiabetic and diabetic hypertensive patients. Am J Hypertens 2001; 14: 908-913
20. Kinoshita M, Shimazu N, Fujita M, Fujimaki Y, Kojima K, Mikuni Y et al. Doxazosin, an alpha1-adrenergic antihypertensive agent, decreases serum oxidized LDL. Am J Hypertens 2001; 14: 267-270
21. Tamasawa N, Matsui J, Ogawa Y, Gotoh T, Hinata T, Murakami H et al. Effect of doxazosin on the size of LDL particle in the type 2 diabetic patients with hypertension. J Diabetes Complications 2000; 14: 135-139
22. Ueshiba H, Tsuboi K, Miyachi Y. Effects of amlodipine on serum levels of adrenal androgens and insulin in hypertensive men with obesity. Horm Metab Res 2001 ; 33: 67-169
23. Beer NA, Jakubowicz DJ, Beer RM, Nestler JE. The calcium channel blocker amlodipine raises serum dehydroepiandrosterone sulfate and androstenedione, but lowers serum cortisol, in insulin-resistant obese and hypertensive men. J Clin Endocrinol Metab 1993; 76: 1464-1469
24. Brook RD. Mechanism of differential effects of antihypertensive agents on serum lipids. Curr Hypertens Rep 2000; 2: 370-377
25. Reneland R, Andersson PE, Haenni A, Lithell H. Metabolic effects of long-term angiotensin-converting enzyme inhibition with fosinopril in patients with essential hypertension: relationship to angiotensin-converting enzyme inhibition. Eur J Clin Pharmacol 1994; 46: 431-436
26. Haenni A, Andersson PE, Lind L, Berne C, Lithell H. Electrolyte changes and metabolic effects of lisinopril/bendrofluazide treatment. Results from a randomized, double-blind study with parallel groups. Am J Hypertens 1994; 7: 615-622
27. Luzio SD, Dunseath G, Owens DR. Acute effects of valsartan on insulin sensitivity in obese, non-hypertensive subjects with and without type 2 diabetes. Horm Metab Res 2002; 34: 271-274
28. Pollare T, Lithell H, Selinus I, Berne C. Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia 1988; 31: 415-420
29. Fukuzawa M, Satoh J, Ohta S, Takahashi K, Miyaguchi S, Qiang X et al. Modulation of tumor necrosis factor-alpha production with anti-hypertensive drugs. Immunopharmacology 2000; 48: 65-74
30. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest 2000; 106: 473-481
31. González-Ortiz M, Martínez-Abundis E, Balcá zar-Munatildeoz BR. Serum leptin concentrations in young insulin-sensitive and insulin-resistant volunteers. Horm Metab Res 2000; 32: 273-276